The Effect of Gemcitabine on Cell Cycle Arrest and microRNA Signatures in Pancreatic Cancer Cells

被引：16

作者：

Namima, Daisuke ^{[1
]}

Fujihara, Shintaro ^{[1
]}

Iwama, Hisakazu ^{[2
]}

Fujita, Koji ^{[1
]}

Matsui, Takanori ^{[1
]}

Nakahara, Mai ^{[1
]}

Okamura, Megumi ^{[1
]}

Hirata, Masahiro ^{[1
]}

Kono, Toshiaki ^{[1
]}

Fujita, Naoki ^{[1
]}

Yamana, Hiroki ^{[1
]}

Kato, Kiyohito ^{[1
]}

Kamada, Hideki ^{[1
]}

Morishita, Asahiro ^{[1
]}

Kobara, Hideki ^{[1
]}

Tsutsui, Kunihiko ^{[2
]}

Masaki, Tsutomu ^{[1
]}

机构：

[1] Kagawa Univ, Dept Gastroenterol & Neurol, Takamatsu, Kagawa, Japan

[2] Kagawa Univ, Life Sci Res Ctr, Takamatsu, Kagawa, Japan

来源：

IN VIVO | 2020年 / 34卷 / 06期

关键词：

Pancreatic neoplasm; gemcitabine; cell cycle; cyclin; microRNA; CHEMOTHERAPY; CARCINOMA; MODULATION; RESISTANCE; APOPTOSIS; RESECTION; TARGETS; GROWTH; RNA; D1;

D O I：

10.21873/invivo.12155

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background/Aim: Gemcitabine, an inhibitor of DNA synthesis, is the gold standard chemotherapeutic agent for pancreatic ductal adenocarcinoma (PDAC). MicroRNAs (miRNAs) play critical roles in cancers, including PDAC. However, less is known about the effect of gemcitabine on PDAC cells and miRNA expression in PDAC. We evaluated the effect of gemcitabine on the cell cycle of PDAC cells in vitro and in vivo and on the miRNA expression profile. Materials and Methods: Effects of gemcitabine on PK-1 and PK-9 cell growth were evaluated using a cell counting kit-8 assay. Xenografted mouse models were used to assess gemcitabine effects in vivo. Results: Gemcitabine inhibited the proliferation and tumour growth of PK-1 cells, and induced S phase cell cycle arrest. Numerous miRNAs were altered upon gemcitabine treatment of PK-1 cells and xenograft models. Conclusion: Altered miRNAs may serve as potential therapeutic targets for improving the efficacy of gemcitabine in PDAC.

引用

页码：3195 / 3203

页数：9

共 35 条

[21] Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine [J].

Morgan, MA ;

Parsels, LA ;

Parsels, JD ;

Mesiwala, AK ;

Maybaum, J ;

Lawrence, TS .

CANCER RESEARCH, 2005, 65 (15) :6835-6842

[22] miRNA in hepatocellular carcinoma [J].

Morishita, Asahiro ;

Masaki, Tsutomu .

HEPATOLOGY RESEARCH, 2015, 45 (02) :128-141

[23] A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer [J].

Neoptolemos, JP ;

Stocken, DD ;

Friess, H ;

Bassi, C ;

Dunn, JA ;

Hickey, H ;

Beger, H ;

Fernandez-Cruz, L ;

Dervenis, C ;

Lacaine, F ;

Falconi, M ;

Pederzoli, P ;

Pap, A ;

Spooner, D ;

Kerr, DJ ;

Büchler, MW .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1200-1210

[24] Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial [J].

Oettle, Helmut ;

Post, Stefan ;

Neuhaus, Peter ;

Gellert, Klaus ;

Langrehr, Jan ;

Ridwelski, Karsten ;

Schramm, Harald ;

Fahlke, Joerg ;

Zuelke, Carl ;

Burkart, Christof ;

Gutberlet, Klaus ;

Kettner, Erika ;

Schmalenberg, Harald ;

Weigang-Koehler, Karin ;

Bechstein, Wolf-Otto ;

Niedergethmann, Marco ;

Schmidt-Wolf, Ingo ;

Roll, Lars ;

Doerken, Bernd ;

Riess, Hanno .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (03) :267-277

[25] NON-CODING RNA MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship [J].

Pasquinelli, Amy E. .

NATURE REVIEWS GENETICS, 2012, 13 (04) :271-282

[26] The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J].

Pourshams, Akram ;

Sepanlou, Sadaf G. ;

Ikuta, Kevin S. ;

Bisignano, Catherine ;

Safiri, Saeid ;

Roshandel, Gholamreza ;

Sharif, Mehdi ;

Khatibian, Morteza ;

Fitzmaurice, Christina ;

Nixon, Molly R. ;

Abbasi, Nooshin ;

Afarideh, Mohsen ;

Ahmadian, Elham ;

Akinyemiju, Tomi ;

Alahdab, Fares ;

Alam, Tahiya ;

Alipour, Vahid ;

Allen, Christine A. ;

Anber, Nahla Hamed ;

Ansari-Moghaddam, Alireza ;

Arabloo, Jalal ;

Badawi, Alaa ;

Bagherzadeh, Mojtaba ;

Belayneh, Yaschilal Muche ;

Biadgo, Belete ;

Bijani, Ali ;

Biondi, Antonio ;

Bjorge, Tone ;

Borzi, Antonio M. ;

Bosetti, Cristina ;

Briko, Andrey Nikolaevich ;

Briko, Nikolay Ivanovich ;

Carreras, Giulia ;

Carvalho, Felix ;

Choi, Jee-Young J. ;

Dinh-Toi Chu ;

Anh Kim Dang ;

Daryani, Ahmad ;

Davitoiu, Dragos Virgil ;

Demoz, Gebre Teklemariam ;

Desai, Rupak ;

Dey, Subhojit ;

Hoa Thi Do ;

Huyen Phuc Do ;

Eftekhari, Aziz ;

Esteghamati, Alireza ;

Farzadfar, Farshad ;

Fernandes, Eduarda ;

Filip, Irina ;

Fischer, Florian .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (12) :934-947

[27] K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment [J].

Rejiba, Soukaina ;

Wack, Severine ;

Aprahamian, Marc ;

Hajri, Amor .

CANCER SCIENCE, 2007, 98 (07) :1128-1136

[28] G1 PHASE PROGRESSION - CYCLING ON CUE [J].

SHERR, CJ .

CELL, 1994, 79 (04) :551-555

[29] miR-582-5P induces colorectal cancer cell proliferation by targeting adenomatous polyposis coli [J].

Shu, Zhenbo ;

Chen, Libo ;

Ding, Dayong .

WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14

[30] Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth [J].

Toyota, Yuka ;

Iwama, Hisakazu ;

Kato, Kiyohito ;

Tani, Joji ;

Katsura, Akiko ;

Miyata, Miwa ;

Fujiwara, Shintaro ;

Fujita, Koji ;

Sakamoto, Teppei ;

Fujimori, Taicayuki ;

Okura, Ryoichi ;

Kobayashi, Kiyoyuki ;

Tadokoro, Tomoko ;

Mimura, Shima ;

Nomura, Takako ;

Miyoshi, Hisaaki ;

Morishita, Asahiro ;

Kamada, Hideki ;

Yoneyama, Hirohito ;

Okano, Keiichi ;

Suzuki, Yasuyuki ;

Masaki, Tsutomu .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (04) :1293-1302

← 1 2 3 4 →